INTERLEUKIN-6 - A FUNCTIONAL AND STRUCTURAL INVITRO MODULATOR OF BETA-CELLS FROM ISLETS OF LANGERHANS

被引：44

作者：

BUSCHARD, K ^{[1
]}

AAEN, K ^{[1
]}

HORN, T ^{[1
]}

VANDAMME, J ^{[1
]}

BENDTZEN, K ^{[1
]}

机构：

[1] KOMMUNE HOSP COPENHAGEN,BARTHOLIN INST,COPENHAGEN,DENMARK

来源：

AUTOIMMUNITY | 1990年 / 5卷 / 03期

关键词：

Electron microscopy; Insulin-dependent diabetes mellitus; Interleukin; 1; 6; Pancreatic islets of Langerhans; Ultrastructure;

D O I：

10.3109/08916939009002977

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The direct in vitro effect of interleukin-6 (IL-6) on pancreatic beta-cells was studied using isolated Lewis rat islets (25/ml/well) precultured for 7 days and then incubated with or without human recombinant 1L-6 (rIL-6) or purified human natural IL-6 (nlL-6). Both sources of IL-6 stimulated insulin secretion over a period of 6 days (P < 0.01). whereas the levels of insulin within the islets were unaffected. At concentrations above 1.5ng/ml, rIL-6 almost doubled the content of insulin in the supernatants. At an intermediate concentration, 0.5ng/ml, rIL-6 preserved insulin secretion by islets cocultured with 2ng/ml of human recombinant interleukin lβ (rIL-Iβ which otherwise inhibited insulin secretion to 60% of islets cultured in medium alone. Electron microscopic studies showed that rIL-6, 1.5ng/ml, caused beta-cell specific degenerative changes similar to those previously described after treatment with IL-1β; i.e. appearance of opaque intracytoplasmic bodies, autophage vacuoles and signs of mitochondrial degeneration. We conclude that human IL-6 stimulates insulin production and secretion in virro and induces similar ultrastructural changes in beta-cells as does IL-Iβ IL-6 may be an endogenous mediator of some of the effects on beta-cells ascribed to IL-1. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.

引用

页码：185 / 194

页数：10

共 35 条

[11]

Campbell I.L., Iscaro A., Harrison L.C., IFN-gamma and tumor necrosis factor-alpha. Cytotoxicity to 1 murine islets of Langerhans, J Immunol, 141, pp. 2325-2329, (1988)

[12]

Bendtzen K., Rasmussen A.K., Bech K., Feldt-Rasmussen U., Buschard K., Pathogenic role of inter-leukin 1 and tumor necrosis factor in autoimmune endocrine diseases, Clin Immunol Newslett, 9, pp. 72-74, (1988)

[13]

Bendtzen K., Immune hormones (cytokines)

[14]

pathogenic role in autoimmune rheumatic and endocrine diseases, Autoimmuniry, 2, pp. 177-189, (1989)

[15]

Nerup J., Mandrup-Poulsen T., Mslvig J., Spinas G., Immune interactions with islet cells: Implications for the pathogenesis of insulin-dependent diabetes mellitus, The Pathology of the Endocrine Pancreas in Diabetes, pp. 71-84, (1989)

[16]

Bendtzen K., Interleukin I., Interleukin 6 and tumor necrosis factor in infection, inflammation and immunity, Immunol Lett, 19, pp. 183-192, (1988)

[17]

Kishimoto T., Hirano T., Molecular regulation of B lymphocyte response, Ann Rev Immunol, 6, pp. 485-512, (1988)

[18]

Brakenhoff J.P., de Groot E.R., Evers R.F., Pannekoek H., Aarden L.A., Molecular cloning and expression of hybridoma growth factor in Escherichia coli, J Immunol, 139, pp. 4116-4121, (1987)

[19]

Lansdorp P.M., Aarden L.A., Calafat J., Zeiljemaker W.P., A growth-factor dependent B-cell hybridoma, Curr Top Microbiol Immunol, 132, pp. 105-113, (1986)

[20]

van Darnme J., van Beeumen J., Decock B., van Snick J., de Ley M., Billiau A., Separation and comparison of two monokines with lymphocyte-activating factor activity: IL-Iβ and hybridoma growth factor (HGF). Identification of leukocyte-derivated HGF as IL-6, J Immunol, 140, pp. 1534-1541, (1988)

← 1 2 3 4 →